非小細胞肺癌市場：KOL 洞察

本報告調查非小細胞肺癌市場，並根據美國和歐洲12位關鍵意見領袖的見解深入探討了 NSCLC 治療的演變格局。 Opdivo 和 Keytruda 成為美國和歐洲的標準，調查新輔助和圍術期 IO 治療方案的成長趨勢。強調需要更好的預後標記來最佳化基於 IO 的輔助治療的患者選擇。也研究了 Summit 的ivonescimab 作為一種新型治療方法的潛力，以及基於 mRNA 的疫苗（如 Moderna 的V940）的令人興奮的前景。

目錄

執行摘要

目前與未來的治療演算法

研究目的

PD-1/L1 為基礎的治療方案

• 核准的治療方法
  • 晚期非小細胞肺癌 (Merck & Co.; BMS; Roche; AstraZeneca; Regeneron; Daiichi Sankyo)
  • 早期非小細胞肺癌 (Merck & Co.; BMS; Roche; AstraZeneca)
• 最近批准的和研發的處理方法
  • Tevimbra (tislelizumab; BeiGene); Cejemly (sugemalimab; CStone); Zynyz (retifanlimab; Incyte); zimberelimab (Arcus Biosciences)

抗CTLA-4單株抗體

• Gotistobart (BNT316/ONC392; OncoC4/BioNTech)
  • 主要見解摘要

抗LAG3藥物

• 研發線療法
  • Fianlimab (Regeneron); Opdualag (relatlimab + nivolumab; BMS); eftilagimod alpha (IMP321; Immutep)

抗TIGIT單株抗體

• 研發線療法
  • Tiragolumab (RG6058; Roche); vibostolimab (MK-7684; Merck & Co.); ociperlimab (BGB-A1217; BeiGene); domvanalimab (AB154; Arcus/Gilead); belrestotug (EOS-448; iTeos/GSK)

抗NKG2A/CD73單株抗體

• Monalizumab (IPH2201; AstraZeneca); oleclumab (AstraZeneca)
  • 主要見解摘要

雙特異性抗體

• 研發線療法
  • Ivonescimab (SMT112; Summit)
  • Acasunlimab (GEN1046/BNT311; Genmab)
  • Volrustomig (MEDI5752; AstraZeneca)

新型免疫檢查點抑制劑（ICI）

• 研發線療法
  • Cobolimab (GSK4069889/TSR-022; AnaptysBio/GSK)

IL15受體促效劑

• 研發線療法
  • Anktiva (N-803/nogapendekin alfa inbakicept; ImmunityBio)

治療性疫苗

• 研發線療法
  • V940 (mRNA-4157; Moderna/Merck & Co.); aglatimagene besadenovec (CAN-2409; Candel Therapeutics)

未來治療趨勢

• 主要見解摘要

附錄

This report delves into the evolving landscape of NSCLC treatments, focusing on insights from 12 key opinion leaders in the USA and Europe. It explores the growing trend of neoadjuvant and perioperative IO-based regimens, with Opdivo and Keytruda becoming standard in the US and Europe. The report highlights the need for better prognostic markers to refine patient selection for IO-based adjuvant therapy. It also examines the potential of Summit's ivonescimab as a novel therapy and the exciting prospects for mRNA-based vaccines like Moderna's V940. Pharmaceutical professionals will gain a comprehensive understanding of current and future treatment pathways.

Key questions answered:

• What are the preferred IO-based regimens for early-stage, locally advanced, and metastatic NSCLC?
• How has the use of approved immunotherapies evolved, and what are the future trends?
• Which clinical trials of immunotherapies have the potential to significantly impact treatment practice?
• What are the most promising pipeline immune therapies, and how might they affect current market players?
• How is the NSCLC immunotherapy treatment landscape expected to change in the near to medium term?
• What are the key clinical data and trials shaping the current treatment algorithm for NSCLC?

Key brands covered in this report:

List of Companies:

Table of Contents

Executive summary

Current and future treatment algorithm

Research objectives

PD-1/L1-based regimens

• Approved therapies
  • Advanced NSCLC (Merck & Co.; BMS; Roche; AstraZeneca; Regeneron; Daiichi Sankyo)
  • Early-stage NSCLC (Merck & Co.; BMS; Roche; AstraZeneca)
• Recently approved and pipeline therapies
  • Tevimbra (tislelizumab; BeiGene); Cejemly (sugemalimab; CStone); Zynyz (retifanlimab; Incyte); zimberelimab (Arcus Biosciences)

Anti-CTLA-4 monoclonal antibodies

• Gotistobart (BNT316/ONC392; OncoC4/BioNTech)
  • Key insights summary

Anti-LAG3 agents

• Pipeline therapies
  • Fianlimab (Regeneron); Opdualag (relatlimab + nivolumab; BMS); eftilagimod alpha (IMP321; Immutep)

Anti-TIGIT monoclonal antibodies

• Pipeline therapies
  • Tiragolumab (RG6058; Roche); vibostolimab (MK-7684; Merck & Co.); ociperlimab (BGB-A1217; BeiGene); domvanalimab (AB154; Arcus/Gilead); belrestotug (EOS-448; iTeos/GSK)

Anti-NKG2A/CD73 monoclonal antibodies

• Monalizumab (IPH2201; AstraZeneca); oleclumab (AstraZeneca)
  • Key insights summary

Bispecific antibodies

• Pipeline therapies
  • Ivonescimab (SMT112; Summit)
  • Acasunlimab (GEN1046/BNT311; Genmab)
  • Volrustomig (MEDI5752; AstraZeneca)

Novel immune checkpoint inhibitors (ICIs)

• Pipeline therapies
  • Cobolimab (GSK4069889/TSR-022; AnaptysBio/GSK)

IL15 receptor agonists

• Pipeline therapies
  • Anktiva (N-803/nogapendekin alfa inbakicept; ImmunityBio)

Therapeutic vaccines

• Pipeline therapies
  • V940 (mRNA-4157; Moderna/Merck & Co.); aglatimagene besadenovec (CAN-2409; Candel Therapeutics)

Future treatment trends

• Key insights summary

Appendix

• KOL details
  • KOLs from the USA
  • KOLs from Europe